Skip to main content

BGB-3111-304 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

April 26, 2018

End Date

April 5, 2024
 

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

April 26, 2018

End Date

April 5, 2024